FDA strengthens warning labels on cholesterol-lowering statins

02/28/2012 | Reuters · New York Times (tiered subscription model), The

The FDA updated prescribing information on labels of cholesterol-lowering statins to include alerts about the risk of increased blood glucose levels, diabetes, memory loss and other health problems. The change was based on a review of medical literature and adverse-event reports. "The value of statins in preventing heart disease has been clearly established," said FDA official Dr. Amy G. Egan. "Their benefit is indisputable, but they need to be taken with care and knowledge of their side effects."

View Full Article in:

Reuters · New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT